Background--Mechanical stimulation of acute ischemic myocardium by shock wave therapy (SWT) is known to improve cardiac function by induction of angiogenesis. However, SWT in chronic heart failure is poorly understood. We aimed to study whether mechanical stimulation upon SWT improves heart function in chronic ischemic heart failure by induction of angiogenesis and postnatal vasculogenesis and to dissect underlying mechanisms.
I
schemic heart disease remains the leading cause of mortality (12.7%) worldwide, causing more than 7 million deaths per year. 1 Infarction of the myocardium causes loss of cardiomyocytes. Remodeling of the infarction zone results in replacement of the necrotic myocardium by fibrotic scar tissue without contractile function. Besides a necrotic infarction core zone, chronically ischemic myocardium persists at the border zone of the infarction. 2 Native angiogenesis after infarction most often is not sufficient for appropriate supply of hibernating cardiomyocytes, leading to pathologic left ventricle (LV) remodeling and ischemic cardiomyopathy, a clinical entity characterized by a poor prognosis and severe symptoms in affected patients. 3 Management of this disease often is limited, and curative strategies beside heart transplantation are lacking. Therefore, therapies enhancing vascularization in the infarction zone by induction of capillary sprouting from existing vessels (angiogenesis) and/or by recruitment of bone marrow-derived endothelial cells (BMEC) for de novo vessel formation (vasculogenesis) are therefore of high relevance. 4, 5 For this purpose, strategies including cell therapy, gene therapy, and growth factor administration have been investigated. 6 Although some clinical benefits have been reported, because of divergent results and safety concerns, none of the described methods has attained broad routine clinical use. 7, 8 Enhancing vascularization of chronically ischemic myocardium remains especially challenging, as production of growth factors for angiogenesis and chemoattractants for vasculogenesis are reduced in chronic fibrotic scars. Shock waves are mechanical pressure waves with a specific physical wave profile used in clinical medicine for >30 years. 9 At low energy levels, shock wave therapy (SWT) is in routine clinical use for the treatment of wound-healing disturbances, [10] [11] [12] tendinopathies, and nonhealing bone fractures. [13] [14] [15] The regenerative effects of SWT have been mainly attributed to the induction of angiogenesis via growth factor release. [16] [17] [18] [19] Therefore, extensive research has been performed on cardiac SWT. In preclinical experiments, shock wave-treated hearts showed an increased number of capillaries and arterioles in the infarction border zone, thereby leading to a significantly improved left ventricular ejection fraction. [20] [21] [22] In clinical studies, SWT caused the improvement of angina symptoms in patients with ischemic heart disease. 23, 24 Moreover, the combined treatment of SWT with subsequent systemic injection of endothelial progenitor cells in human patients with infarction has been investigated and showed convincing results by means of left ventricular ejection fraction improvement. 25 In an experimental model of hindlimb ischemia, we showed that even endogenous endothelial progenitor cells become mobilized to systemic circulation upon SWT. 26, 27 However, their origin has not been identified so far.
In the present study we hypothesized that besides angiogenesis, cardiac SWT also induces the recruitment of BMECs to chronically ischemic myocardium. We propose involvement of heparan sulfate proteoglycan (HSPG)-bound growth factors in the extracellular matrix after the physical stimulus of SWT as an underlying mechanism. Angiogenic growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are bound to the heparin-binding domain of HSPGs in the extracellular matrix (ECM). 28, 29 The polysaccharides composed of a core protein and glycosamine chains have been described as mechanosensors orchestrating pivotal cellular functions upon mechanical force or tissue injury by growth factor release and subsequent induction of angiogenesis and tissue repair. 30 In particular, the isoform VEGF 165 is bound to HSPGs on the cellular surface. 31 We aimed to analyze whether SWT would improve heart function by induction of angiogenesis and vasculogenesis in a model of chronic ischemic heart disease.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Animals
All procedures involving animals were approved by the national Animal Care and Use Committee, file number: BMWFW-66.011/0138-WF/V/3b/2014. Surgical procedures and animal care were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, volume 25, number 28, revised 1996), EU Directive 86/609 EEC, and Austrian Protection of Animals Act.
Clinical Perspective
What Is New?
• Shock wave therapy (SWT) improves cardiac function in a murine model of chronic ischemic cardiomyopathy by induction of angiogenesis and vasculogenesis and decreases myocardial fibrosis.
• Vascular endothelial growth factor release from heparan sulfate proteoglycans results in enhanced endothelial cell proliferation, enhanced survival, and capillary sprouting.
• Shock wave therapy induces enhanced expression of the chemoattractant stromal cell-derived factor 1 in ischemic myocardium and serum and results in higher numbers of bone marrow-derived endothelial cells at the site of injury.
What Are the Clinical Implications?
• Shock wave therapy develops a promising regenerative treatment option for patients with ischemic cardiomyopathy. It could serve as a promotor of "endogenous cell therapy" without exhibiting the disadvantages of cell harvesting necessary for conventional cell therapy.
• In more than 3 decades of medical application, no severe side effects have been described. • Thus, shock wave therapy for regeneration of ischemic myocardium could be translated into a clinical setting efficiently.
Investigators blinded to the treatment of the animals performed measurements and analysis. Twelve-to 14-weekold male C57BL/6 wild-type mice (Charles River, Sulzfeld, Germany) weighing 25 to 30 g housed in the biomedical research facility of the Medical University of Innsbruck were randomly divided into treatment groups. During the experiments, mice were housed under standard conditions with a 12-hour light/dark cycle. Water and commercial mouse diet were available ad libitum.
Myocardial Infarction Model
Anesthesia was administered by an intraperitoneal injection of ketamine hydrochloride 80 mg/kg (Graeub, Bern, Switzerland) and xylazine hydrochloride 5 mg/kg (aniMedica, Senden-Bosensell, Germany). After endotracheal intubation and mechanical ventilation, the heart was exposed through a thoracotomy at the fourth intercostal space. Myocardial infarction was induced as described previously. 22 
SW Treatment
Animals received SWT 3 weeks after left anterior descending (LAD) ligation in a setting of chronic myocardial ischemia under anesthesia to the area of the anterior wall. Common ultrasound gel was used for coupling. The commercially available Orthogold device (TRT LLC, Tissue Regeneration Technologies, Woodstock, GA) served as shock wave source. For the in vivo application, 300 impulses were delivered to the ischemic area with an energy flux density of 0.38 mJ/mm 2 at a frequency of 4 Hz. However, for all in vitro experiments 250 impulses with an energy flux density of 0.1 mJ/mm 2 at a frequency of 3 Hz were used. The rationale of the treatment parameters is our experience from previous studies. 32 At this low-energy level, no adverse effects were observed. For the application of SWT to cultured cells, a specifically designed water bath was used as described previously. 32 
Bone Marrow Transplantation Model
The bone marrow transplantation model was performed as described previously. 33 
Echocardiography
Transthoracic echocardiography was performed using standard protocols for the assessment of heart function and morphometry. Briefly, lightly anaesthetized mice (0.5% isoflurane and 99.5% O 2 ) were placed on a temperature-controlled warming pad (kept at 37.5°C) and imaged in the supine position using a high-resolution micro-imaging system equipped with a 30-MHz linear array transducer (Vevo770 Imaging System; VisualSonics Inc, Canada), respectively. Standard 2-dimensional-and M-mode tracings of the LV (long axis and short axis at papillary muscle level) were recorded and LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), intraventricular septum thickness, and LV posterior wall thickness were averaged from 3 consecutive cardiac cycles under stable conditions. Fractional shortening was calculated using the equation: 1009((LVEDDÀLVESD)/ LVEDD). The investigator was blinded to the treatment.
Hemodynamic Pressure-Volume Measurements
Invasive hemodynamic measurements and the analysis of pressure-volume loops were performed as terminal procedure according to established protocols using a pressure-volume conductance system (MPVS Ultra, Millar Instruments, USA) connected to the PowerLab 8/35 data acquisition system and analyzed using LabChart7pro software system (both ADInstruments, Sydney, Australia). Mice were anesthetized (3% isoflurane and 96%-97% O 2 ), intubated, and mechanically ventilated. The animals were placed on a temperaturecontrolled heating platform and the core temperature was maintained at 37.5°C. Anesthesia was reduced and kept at 1.5% isoflurane and 98.5% O 2 . A polyethylene catheter was inserted into the right external jugular vein for saline calibration (10% NaCl) at the end of the experiment to calculate the parallel volume. The 1.4-F pressure-volume conductance catheter (SPR-839, Millar, USA) was inserted into the right carotid artery and advanced into the ascending aorta. Aortic (systemic) blood pressure and heart rate were recorded after stabilization for 5 minutes. Then the catheter was advanced into the LV under pressure control through the aortic valve as described previously. 
Endothelial Cell Proliferation Assay
Endothelial cell proliferation after SWT was analyzed as described previously. 33 
Aortic Ring Assay
The aortic ring assay was performed as described previously. 37 
Apoptosis Assay
Cells were pretreated with inhibitors as described under Endothelial Cell Proliferation Assay, treated with SWT, and serum starved in serum-free EBM-2 medium for 18 hours.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed as recommended by the manufacturer (Roche, Rotkreuz, Switzerland). Cells positive for TUNEL staining and for 4 0 ,diamidino-2-phenylindole (DAPI) staining were counted and results are expressed as percentage of TUNEL-positive cells of all DAPI-stained cells. 33 
Migration Assay
A modified Boyden chamber assay was performed as described previously. 38 
Cytokine Array
Supernatant from SW-treated HUVECs was analyzed using a human cytokine array kit as suggested by the manufacturer (human cytokine array kit; R&D Systems, Minneapolis, MN). Pixel density of membranes was quantified using Image J software (NIH, Bethesda, MD).
Western Blotting
Western blotting was performed as described previously.
39
Stromal Cell-Derived Factor-1 Enzyme-Linked Immunosorbent Assay
Stromal cell-derived factor-1 (SDF-1) levels were quantified in murine serum 72 hours after treatment (n=6). Enzyme-linked immunosorbent assay was performed according to the manufacturer's instructions (R&D Systems, Minneapolis, MN). Detection of the concentration was performed using a microplate reader. Data are shown in nanograms per milliliter.
Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted from homogenized tissue using the RNAII Kit (Machery-Nagel; D€ uren, Germany) according to the 
Immunofluorescence Staining
Immunofluorescence staining was performed as described previously. 39 
Masson-Trichrome Staining
For histological analysis, grafts were fixed in 4% (vol/vol) buffered formaldehyde, dehydrated with graded ethanol series, and embedded in paraffin. Masson-trichrome staining was performed as recommended by the manufacturer (Carl Roth, Karlsruhe, Germany). The area of fibrosis and total area of the LV were measured using ImageJ (NIH, Bethesda, MD).
Values are shown as infarction size (ratio: LV fibrosis/total area LV) as described previously.
Statistical Analysis
All results are expressed as meanAESEM. Data sets were analyzed for normal distribution using the KolmogorovSmirnov test. If samples were normally distributed, a Student t test was performed for comparison between 2 groups. In the case of nonparametric distribution, a Mann-Whitney test was performed. Multiple groups were analyzed by 1-way ANOVA test followed by Bonferroni's Multiple Comparison Test to determine statistical significance. Probability values <0.05 were considered statistically significant. All experiments were repeated at least in triplicate.
For further details regarding materials and methods, see Data S1.
Results
Chronic Ischemic Heart Failure: Functional Improvement by SWT C57BL/6 mice were treated with SWT in a chronic infarction model (3 weeks after LAD ligation, n=6 per group). Cardiac function was measured 4 weeks after treatment using transthoracic echocardiography and a pressure-volume catheter. Hearts were harvested subsequently for histological analyses ( Figure 1A Figure 1D ).
Cardiac function was evaluated additionally via invasive hemodynamic pressure-volume measurement (representative pressure-volume loops Figure 1E ). Improvement of LV function and myocardial contractility by SWT Figure 2D ). While VEGF and FGF stimulate capillary sprouting by induction of endothelial proliferation and migration, placental growth factor induces maturation and stabilization of vessels contributing to arteriogenesis.
Vascularization in ischemic myocardium therefore was visualized by immunofluorescence staining for CD31 (endothelial cells, capillaries) and a-smooth muscle actin, smooth muscle cells, and arterioles ( Figure 2E) . A higher blood vessel density was found in the peri-infarct regions of shockwavetreated animals compared with untreated controls. Significantly higher numbers of capillaries ( Figure 2F) Figure 2G ) were observed in the treatment group. These observations indicate induction of angiogenesis and arteriogenesis in the infarct border zone of chronically ischemic myocardium by SWT.
Shock-Wave Effects on Endothelial Cells and Angiogenesis Ex Vivo
Two protein kinases play a crucial role during angiogenesis: activation of mitogen-activated p42/44 ERK1/2 regulates endothelial cell proliferation, while activation of Akt/protein kinase B is required for remodeling of the cytoskeleton and concomitant cell migration. Both kinases are activated by phosphorylation. SWT of HUVECs resulted in phosphorylation of Akt after 30 minutes. ERK was activated by SWT after 30 minutes and, as a second peak, after 4 and 6 hours ( Figure 3A ). This resulted in induction of endothelial proliferation after SWT (number of DAPI-positive cells/HPF: CTR 66.28AE4.70 versus SWT 100.9AE4.19, P<0.001) ( Figure 3B ). To investigate SW effects on cell survival, HUVECs were starved, treated, and subsequently analyzed via TUNEL assay. We found an anti-apoptotic effect of SWT (% of TUNEL-positive cells: CTR 13.91AE1.97 versus SWT 4.99AE1.36, P=0.0006) ( Figure 3B ). To verify whether the observed effects do in fact lead to capillary sprouting, we performed an aortic ring assay. For this purpose, murine aortas were cultured in matrigel and treated with SWT, whereas controls remained untreated. After 7 days, capillary sprouts were quantified. SWT induced significantly increased capillary sprouting compared with untreated controls (number of sprouts/HPF: CTR 0.36AE0. 
Shock Wave Effects Depend on VEGF Signaling
VEGF signaling has been shown to play a major role in SWinduced angiogenesis. We aimed to clarify whether observed effects were in fact VEGF dependent and whether VEGFR2 stimulation and consecutive MAPK activation were responsible for angiogenesis after treatment. Inhibition of VEGFR2 via vandetanib (100 nm and 1 lm) abolished phosphorylation of Akt and ERK 30 minutes after SWT, clearly indicating that SWinduced activation of MAPK is VEGFR2 dependent ( Figure 4A 
HSPG Bound Growth Factors Mediate SW Effects
The ECM contains growth factors from the VEGF and FGF families bound to HSPGs. Thus, growth factors can be provided rapidly in case of tissue injury for tissue repair. Prolonged ERK activation might indicate effects of HSPGbound growth factors in SWT stimulation. Therefore, heparin and heparinase were tested to influence SWT effects on endothelial cells and ex vivo angiogenesis. We pretreated HUVECs with heparinase (50 mU) or heparin (10 lg/mL) for growth factor depletion of the ECM. 41 Figure 5C ). These results indicate that HSPG- bound growth factors are involved in angiogenesis after SWT.
SWT Stimulates Vasculogenesis in Chronic Ischemic Heart Failure
We aimed to address whether SWT stimulates vasculogenesis by recruitment of bone marrow-derived endothelial cells to chronically ischemic myocardium. In order to evaluate shockwave-induced vasculogenesis in vivo, wild-type mice received bone marrow transplantation from GFP donor mice (n=6 per group). Subsequently, animals underwent LAD ligation. After myocardial remodeling (3 weeks), chronically ischemic myocardium received SWT ( Figure 6A ). SWT enhanced incorporation of BMECs, as shown by increased numbers of cells double positive for rhodamine-labeled isolectin (injected intravenously for staining of host vessels) and for GFP (representing bone marrow-derived cells after Figure 4 . Shock wave effects depend on VEGF signaling. A, Activation of Akt and ERK is abolished upon VEGFR2 inhibition. Early phosphorylation of Akt as well as ERK after SWT was inhibited by pretreatment of cells with VEGFR2 inhibitor vandetanib. All experiments were performed at least in triplicate. B, SW-induced endothelial cell proliferation is VEGFR2 dependent. HUVECs were pretreated with VEGF antibody or vandetanib and subsequently underwent SWT, and DAPI-stained nuclei were quantified 24 h after treatment. VEGF inhibition and VEGFR2 inhibition both resulted in neutralization of the proliferative SW effect. (scale bar=100 lm) (*P<0.05 vs CTR). All experiments were performed at least in triplicate. C, VEGFR2 inhibition neutralizes anti-apoptotic SW effect. HUVECs were starved, treated with VEGF antibody or VEGFR2 inhibitor, treated with SWT, and subsequently analyzed for apoptosis by TUNEL assay. SWT enhanced endothelial cell survival; however, effects were abolished with VEGF antibody or vandetanib pretreatment. (scale bar=100 lm) (*P<0.05 vs CTR). All experiments were performed at least in triplicate. D, Capillary sprouting after SWT is VEGFR2 dependent. Murine aortas were pretreated with VEGF antibody or VEGFR2 inhibitor and subsequently received SWT. Capillary sprouting after SWT was inhibited by VEGF antibody or VEGFR2 inhibitor pretreatment. (n=6 per group, *P<0.05 vs CTR). Akt indicates proteinkinase b; CTR, control; DAPI, 4 0 ,diamidino-2-phenylindole; ERK, extracellular-signal regulated kinase; HPF, high-power field; INH, inhibitor; HUVEC, human umbilical vein endothelial cell; SWT, shock wave therapy; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; VEGFR2, vascular endothelial growth factor receptor 2.
bone marrow transplantation). Examination of double-positive cells per HPF revealed significantly higher numbers of BMECs in the SWT group compared with untreated controls (BMECs/ HPF: CTR 3.98AE0.6 versus SWT 17.89AE1.59, P<0.0001) ( Figure 6B, arrowheads) .
SDF-1 serves as one of the most potent chemoattractants for the recruitment of endothelial cells from the bone marrow. To evaluate in vivo SDF-1 levels after SWT Western blot, analysis of treated myocardium was performed from periinfarct samples (n=5) and it was confirmed that myocardial SDF-1 protein levels were increased in the treatment group ( Figure 6C ). To analyze systemic chemotaxis upon SWT, we performed an SDF-1 ELISA from blood serum 72 hours after treatment. We found higher levels of SDF-1 in the circulation of treated animals (ng/mL: CTR 1.16AE0.18 versus SWT 1.88AE0.12, P=0.0102) ( Figure 6D ). In parallel, mRNA levels of the SDF-1-specific receptor C-X-C chemokine receptor type 4 were increased in treated myocardium (relative gene Figure 6F ). Indeed, preconditioned medium of ischemic cardiomyocytes treated with SWT induced chemotaxis of endothelial cells in a modified Boyden chamber migration assay (number of cells/ HPF: CTR 645.0AE8.0 versus SWT 758.0AE17.62, P=0.017) ( Figure 6G ). Pretreatment of HUVECs with heparinase or heparin both abolished SW effects on cell proliferation. (scale bar=100 lm) (*P<0.05 vs CTR). All experiments were performed at least in triplicate. B, Improved cell survival after SWT is inhibited upon treatment with heparin and heparinase. Starved HUVECs showed no improved survival after SWT when pretreated with heparin or heparinase. (scale bar=100 lm) (*P<0.05 vs CTR). All experiments were performed at least in triplicate. C, Cleavage of heparin and heparin sulfate abolished SW-induced capillary sprouting. Pretreatment with heparin and heparinase neutralized capillary sprouting after SWT in a murine aortic ring assay hinting towards pivotal involvement of HSPG in SW-mediated angiogenesis. (n=6 per group, *P<0.05 vs CTR). CTR indicates control; DAPI, 4 0 ,diamidino-2-phenylindole; HPF, high-power field; HSPG, heparan sulfate proteoglycan; HUVEC, human umbilical vein endothelial cell; SWT, shock wave therapy; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.
Discussion
In previous publications, we demonstrated VEGF release and subsequent angiogenesis in acute models of hindlimb and myocardial ischemia after SWT. 16, 22, 39 In daily clinical practice, however, chronic ischemic heart failure represents an even more challenging problem because of limited therapy and poor prognosis of this disease. The aims of this study therefore were to use a model of chronic ischemic heart disease and to investigate the pathophysiology of heart failure with and without SWT and additionally to dissect underlying mechanisms. Measurements by echocardiography as well as invasively by catheter showed improved systolic and diastolic heart function by SWT. In a porcine study, Uwatoku et al found improvement of cardiac function when applied directly after induction of myocardial infarction by preventing postinfarction remodeling. However, there was no beneficial SW effect on chronic ischemic myocardium in their setting. 42 This discrepancy might be because of the divergent models of myocardial ischemia induction, because the group used excision of the circumflex artery, whereas in our model LAD ligation was performed. Histology revealed decreased fibrosis, increased density of blood vessels, and recruitment of bone marrow-derived endothelial cells. In the chronic ischemic myocardium, pivotal angiogenic (VEGF and FGF) and vasculogenic factors (SDF-1) as well as respective receptors were upregulated by SWT. Mechanistically, SWT stimulated endothelial cell proliferation, inhibited apoptosis, and activated intracellular protein kinases Akt and ERK, and inhibition of effects by blockade of VEGFR2 indicates an important role of VEGF signaling in SWT response. A late second peak of ERK activation after 4 hours prompted us to evaluate whether growth factors bound to HSPGs mediate effects of SWT. 33 Currently it remains unknown how the mechanical stimulus of SWT stimulates VEGF signaling. A recent study showed crucial involvement of the mechanosensors caveolin-1 and ß1-integrin in SW-induced mechanotransduction, because angiogenic response was clearly reduced after knock-down of the proteins. 43 However, because numerous immediate angiogenic effects of SWT have been described, we aimed to investigate the release of stored growth factors rather than de novo synthesis. The cellular VEGF reservoir is mainly found in the ECM bound to HSPGs. 31 HSPGs were described as mechanosensors that are involved in orchestration of angiogenesis and endothelial cell migration. We therefore hypothesized that the mechanical stimulus of SWT leads to growth factor release or redistribution from HSPGs facilitating binding of factors such as VEGF to its receptors. We confirmed that pretreatment of HUVECs with heparinase I and III for cleavage of heparin and heparin sulfate of HSPG and subsequent disruption of HSPG 30 abolished SWT-induced phosphorylation of Akt and ERK, endothelial cell proliferation, and enhanced survival and capillary sprouting. Although we did not find increased VEGF concentrations in supernatants of SWTtreated cells (data not shown), it is conceivable that SWT induces redistribution of growth factors in the ECM, thus facilitating growth factor binding to the receptors. Neutralization of VEGF using a VEGF antibody antagonized angiogenic SW effects in vitro, as did inhibition of VEGFR2. In combination with our data of impaired SWT effects after heparinase, we therefore suggest that SWT induces angiogenesis via VEGF release/redistribution from extracellular HSPGs. Released VEGF binds to VEGFR2 and thus initiates angiogenesis. We already showed in a previous publication that SWT stimulates phosphorylation/activation of VEGFR2 without further cytokine stimulation. 16 Moreover, we aimed to analyze whether the newly formed vessels after SWT originate from angiogenesis or whether postnatal vasculogenesis is also involved. We determined previously that SWT increases the number of CD34-positive cells in the peripheral blood. 26 Additionally, it was described that SWT enhances the recruitment of intravenously injected endothelial progenitor cells to ischemic hindlimbs. 27 However, it was not yet known whether SW treatment also enhances the recruitment and homing of endogenous bone marrowderived endothelial cells to the site of ischemic injury to induce de novo synthesis of blood vessels within chronic ischemic myocardium. To study this question, wild-type mice received bone marrow transplantation from GFP donor mice, and underwent LAD ligation and SWT. BMECs could be identified as GFP+ endothelial cells within the myocardium. We found significantly more BMECs after SWT, showing for the first time that SWT does enhance recruitment and homing of autologous bone marrow-derived endothelial cells to chronic ischemic myocardium. SDF-1, a pivotal chemoattractant for BMECs, 27 was upregulated by SWT in the myocardium and in serum of treated animals as was the SDF receptor C-X-C chemokine receptor type 4 in myocardium. Additionally, we found enhanced expression of chemokines important for BMEC migration such as IL-6, IL-8, monocyte chemoattractant protein 1, and migration inhibitory factor after SWT. These data indicate that SWT applied to the chronic ischemic myocardium induces not only angiogenesis but also postnatal vasculogenesis. Summarizing, we found improved cardiac function by SWT in a model of chronic ischemic heart failure as measured by echocardiography and invasively by catheter, detected reduction of fibrotic scar tissue, and improved neovascularization via angiogenesis and postnatal vasculogenesis. We were able to show that the mechanical impulse of SWT translates to a HSPGand VEGF-dependent stimulation of intracellular signal transduction pathways, increased proliferation and inhibition of apoptosis in vitro and stimulation of capillary sprouting ex vivo in aortic rings. Inhibition of these effects by heparinase and by blocking of VEGF and VEGFR2 indicates a pivotal role of VEGFR2 stimulated by ECM-stored VEGF in SWT-induced angiogenesis.
Recently, we demonstrated improved angiogenesis and subsequent improvement of heart function in a model of acute myocardial ischemia. 22 However, in this study we were able to show for the first time improved vascularization in chronically ischemic myocardium and concomitant improvement of cardiac function. This is highly significant, because regenerative therapy options to improve heart function are limited for the increasing number of patients with chronic ischemic heart failure.
SWT could serve as a promotor of "endogenous cell therapy" without exhibiting the disadvantages of cell harvesting necessary for conventional cell therapy. In addition, longterm effects of SWT are well known, because it has been used in medicine for more than 3 decades. No severe side effects were described after SWT. Thus, SWT for regeneration of ischemic myocardium could be translated into a clinical setting efficiently. 44 
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Hemodynamic measurements
Parameters of systolic and diastolic function, including LV end-systolic pressure (LVESP), LV end-diastolic pressure (LVEDP), LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV), stroke volume (SV), cardiac output (CO), arterial elastance (Ea) as a measure of ventricular afterload, ejection fraction (EF), maximal slope of LV systolic pressure increment (dP/dtmax), maximal slope of diastolic pressure decrement (dP/dtmin) and isovolumetric relaxation time constant tau (Tau) were measured and calculated according to standard formulas. After baseline measurements, transient occlusion of the inferior vena cava was performed and used to derive end-systolic and end-diastolic pressure volume relationships as load-independent measures of cardiac contractility and relaxation, respectively. Heart rate was separately measured via surface ECG electrodes.
Myocardial Infarction model
Myocardial infarction was induced by LAD ligation with a 7-0 polypropylene suture at the level of the pulmonary artery. Animals were randomized in a blinded fashion to one of 2 experimental groups: control group (receiving no treatment) and SWT group. Treatment was performed 3 weeks after LAD ligation in a setting of chronic myocardial ischemia. Animals were sacrificed 72h and 4 weeks after treatment (n=6 per group and timepoint). Heart muscle obtained 72h after treatment was homogenized for subsequent RNA isolation for RT-PCR and protein isolation for western blotting, whereas muscle tissue obtained 4 weeks after treatment was half cryo-embedded (for immunofluorescence) and half paraffin embedded (for MassonTrichrome staining). In addition, serum was obtained. For serum sampling, blood was withdrawn and clotting was performed for 15 minutes. Then samples were centrifuged with 3000 RPM for 10 minutes at 4°C. Serum supernatant was transferred to a new tube and then stored at -80°C for further processing.
Aortic ring assay
The thoracic aorta from 12-14 week old C57BL/6 mice (Charles River Laboratories, Sulzfeld, Germany) was obtained under sterile conditions and cut into 1 mm rings. Aortic pieces were incubated with Opti-MEM + GlutaMAX-1 Medium (Gibco, Life Technologies, Grand Island, NY) for 24 hours. Rings in the treatment group were treated in a water bath as described above.
Control groups were treated equally without shock wave application. Subsequently, rings were embedded into collagen matrix containing DMEM Medium (Gibco, Life Technologies, Grand Island, NY) and 1mg/ml type I rat tail collagen (Millipore, Billerica, MA) in 96 well plates. Growth medium was changed first on day 3 and then every second day until the end of the experiment.
Rings were pretreated with inhibitors as described in "Endothelial cell proliferation assay". Aortic rings were observed over a period of 7 days. Main sprouts were counted by phase contrast microscopy. Additionally, rings were stained after fixation with 4% paraformaldehyde using rabbit polyclonal anti-CD31 antibodies (Abcam, Cambridge, UK) and Alexa488 antirabbit secondary antibodies (Invitrogen, Carlsbad, CA).
RT-PCR
The following primers were used:
Gene
Assay on demand VEGF Mm01281449_m1
VEGFR2 Mm01222421_m1
PlGF Mm00435613_m1
